HPV Genotyping (Sixteen Genotypes) by RT PCR

Cancer

Report in 48Hrs

At Home

No Fasting Required

Details

Detects & types HPV DNA.

₹4,440₹6,343

30% OFF

HPV Genotyping (Sixteen Genotypes) by RT PCR - Comprehensive Medical Guide

Why is it done?
- Test Purpose: Detects and identifies specific Human Papillomavirus (HPV) genotypes from cervical, anal, oral, or other tissue samples using Reverse Transcription Polymerase Chain Reaction (RT-PCR) technology to identify up to 16 different HPV types
- Primary Indications: Identification of high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) associated with cervical cancer and other anogenital malignancies; identification of low-risk genotypes (6, 11) associated with benign lesions
- Clinical Applications: Cervical cancer screening and risk stratification; triage of abnormal Pap smears; evaluation of genital warts; assessment of recurrent or persistent HPV infections; patient counseling and risk assessment; treatment planning and prognosis determination
- Typical Timing: Performed when abnormal cytology results occur (ASC-US, LSIL, HSIL); during follow-up of previously positive HPV tests; as part of primary HPV screening in some settings; when evaluating anogenital lesions or malignancies; typically in women aged 25-65 years, though may be used in other age groups in specific circumstances
Normal Range
- Normal Result: Negative for all 16 HPV genotypes tested; reported as 'HPV Not Detected' or 'Negative'
- Result Reporting: Binary format - test results are reported as either Positive (detected) or Negative (not detected); when positive, specific genotypes identified are listed (e.g., HPV 16, HPV 18, HPV 31, etc.)
- Genotype Categories: High-risk (oncogenic) genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 Low-risk (non-oncogenic) genotypes: 6, 11
- Units of Measurement: Qualitative analysis (presence/absence); RT-PCR provides qualitative detection and genotype identification; may include cycle threshold (Ct) values indicating viral load (lower Ct = higher viral load)
- Interpretation: Negative result = No HPV genotypes detected = Lower cancer risk; Positive for low-risk genotypes = Risk for benign lesions (warts); Positive for high-risk genotypes = Increased cancer risk requiring monitoring/treatment; Multiple genotypes detected = Multiple infections present
Interpretation
- Negative Result: No HPV genotypes detected; indicates absence of HPV infection or viral load below detection threshold; low risk for HPV-related disease; recommended for routine cervical cancer screening intervals
- Positive for High-Risk Genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68): Indicates infection with oncogenic HPV types; significant risk for cervical intraepithelial neoplasia (CIN) and cervical cancer; HPV-16 and HPV-18 carry highest cancer risk; requires close clinical follow-up with colposcopy evaluation; may warrant antiviral or immunological interventions
- Positive for Low-Risk Genotypes (6, 11): Indicates infection with non-oncogenic HPV types; associated with benign genital warts (condyloma acuminata); minimal cancer risk; may resolve spontaneously or require symptomatic treatment; regular screening still recommended
- Multiple Genotypes Detected: Indicates co-infection with multiple HPV types; may indicate higher risk profile; requires classification by risk category and appropriate management; infection may occur simultaneously or sequentially
- Clinical Significance of HPV-16 and HPV-18: HPV-16 causes approximately 50% of cervical cancers; HPV-18 causes approximately 20% of cervical cancers; detection warrants aggressive monitoring and possible preventive interventions; identification allows for targeted HPV vaccination in non-infected individuals
- Factors Affecting Results: Sample quality and adequacy; timing of sample collection (viral shedding varies); immune status of patient; presence of concurrent infections; specimen contamination; storage and handling conditions; laboratory methodology and sensitivity thresholds; recent sexual activity may affect viral load detection
- Persistent vs. Transient Infection: Single positive test indicates detection but does not distinguish persistence; repeat testing 12 months after positive result determines if infection is persistent (higher malignancy risk) or cleared spontaneously; persistent high-risk HPV infection associated with progression to CIN and cervical cancer
Associated Organs
- Primary Organs Affected: Cervix (primary site); vagina and vulva; anal canal; oropharynx; larynx; rectum; other squamous epithelial tissues; urinary bladder and urethra (less common)
- Reproductive and Genital System: HPV infection of cervical tissue is the primary concern; can lead to cervical dysplasia, cervical intraepithelial neoplasia (CIN), and invasive cervical cancer if persistent high-risk genotypes remain undetected or untreated
- Associated Malignancies: Cervical cancer (most common); anal cancer; vulvar and vaginal cancers; penile cancer (in males); oropharyngeal cancer; recurrent respiratory papillomatosis (caused by low-risk types 6, 11); adenocarcinoma of the cervix
- Benign Lesions: Condyloma acuminata (genital warts) caused by low-risk HPV types 6 and 11; may cause discomfort, itching, or bleeding; generally does not progress to malignancy but may recur
- Potential Complications: Progression to malignancy (particularly with high-risk types); development of precancerous lesions; psychological impact from positive results; fertility concerns if advanced disease develops; need for invasive procedures (colposcopy, biopsy) for diagnosis and treatment
- Immune System Implications: Immunocompromised individuals (HIV+, transplant recipients) have higher rates of HPV persistence and progression; recurrent or persistent infections more likely in immunosuppressed patients; immune status directly influences disease outcomes and malignancy risk
Follow-up Tests
- If HPV Positive (High-Risk): Colposcopy with cervical biopsy if cytology abnormal; cervical cytology (Pap smear) if not recently performed; repeat HPV testing at 12 months to determine persistence; liquid-based cytology for detailed analysis; HPV testing of male partners (if indicated); assessment for other STIs
- If HPV Negative: Continue routine cervical cancer screening per guidelines (typically every 3-5 years); repeat HPV testing in 3 years (or per institutional protocol); routine Pap smear may be optional depending on screening guidelines; counseling regarding HPV prevention and vaccination
- Complementary Testing: p16/Ki-67 immunocytochemistry (to assess malignancy risk); E6/E7 mRNA testing (to confirm active viral infection); reflex cytology testing (automatically performed based on HPV result); HPV virology testing for oropharyngeal or anal sites if clinically indicated
- Diagnostic Procedures for Positive Results: Colposcopy (visualization of cervix with magnification); cervical biopsy (tissue sampling for histology); endocervical curettage (assessment of endocervical canal); excisional biopsy (loop electrosurgical excision procedure - LEEP); cone biopsy (for diagnosis and treatment)
- Monitoring Frequency: HPV positive patients: HPV testing at 12 months post-treatment or diagnosis; if HPV persistence confirmed, more aggressive intervention may be warranted; HPV negative patients: return to routine screening intervals (typically 3-5 years); post-treatment surveillance may require more frequent testing for 25 years
- Related Tests for Risk Assessment: HPV DNA/RNA viral load testing; HPV serology (antibody testing); genetic susceptibility testing (if indicated); immunological function testing (for immunocompromised patients); screening for cervical adenocarcinoma markers (if HPV-18 positive)
Fasting Required?
- Fasting: No fasting is required for HPV genotyping testing
- Sample Collection Instructions: Cervical sample: Obtained during gynecologic examination using cervical brush or swab; collected in appropriate transport medium; sample should be collected from the endocervix and transformation zone for optimal HPV detection
- Timing Considerations: Avoid menstruation (if possible) as blood may interfere with testing; avoid vaginal douching 24 hours prior to collection; avoid intravaginal medications or products 24-48 hours before sample collection; avoid sexual activity 24-48 hours before sample collection for optimal results
- Medications and Preparations: No medications need to be avoided specifically for this test; notify healthcare provider of any intravaginal medications currently in use; antibiotic use does not typically affect HPV detection; immunosuppressive medications should be documented as they may affect viral load and test interpretation
- Sample Handling: Proper transport medium must be used to preserve sample integrity; samples should be processed within specified timeframe (typically 14-30 days depending on storage conditions); temperature control and storage according to laboratory specifications; improper handling may result in false negative results or test rejection
- Patient Information and Consent: Informed consent recommended, particularly discussing positive result implications; patient should be aware of test purpose and follow-up requirements; counseling regarding safe sexual practices, HPV transmission, and preventive measures; discussion of HPV vaccination options if appropriate for age and status

How our test process works!